Navigation Links
Pathology study tracks uterine changes with mifepristone
Date:3/7/2011

Research continues to show that the controversial abortion drug mifepristone might have another use, as a therapeutic option besides hysterectomy for women who suffer from severe symptoms associated with uterine fibroids.

The University of Rochester Medical Center in 2004 began investigating mifepristone, in a class of drugs known as progesterone receptor modulators (PRMs), to treat fibroids, which affect roughly half of all women younger than 50. Results showed the drug shrank the fibroids and greatly improved the quality of life for the women involved in the clinical trial.

But concern over whether PRMs could cause tissue changes that signal uterine cancer dampened a growing interest in the drug. The latest URMC study demonstrates that PRMs do not appear to trigger cancerous or pre-cancerous lesions in the lining of the uterus, at least in the short term, according to an article in the journal Human Pathology.

"Our biggest concern was cancer, and although we saw significant changes in the endometrial tissue specific to the action of PRMs, all of the changes were benign and well characterized in the laboratory," said lead investigator Julietta Fiscella, M.D., clinical assistant professor of Pathology and Laboratory Medicine at URMC and Director of Pathology at Highland Hospital, an affiliate of URMC.

Fiscella analyzed 152 tissue samples from 53 premenopausal women in the Rochester, N.Y., area, who volunteered to take mifepristone at very low doses for up to 18 months to alleviate miserable symptoms such as pain and heavy bleeding. She compared samples of unexposed endometrial tissue to samples from women who took the drug in 2.5 mg or 5 mg dosages. (To end an unwanted pregnancy, mifepristone is given in a single-day dose of 200 to 600 mg.)

The changes most evident in the drug-exposed tissue included fluid-filled glands that appeared as scattered, benign cysts of varying size, and some abnormal blood vessel
'/>"/>

Contact: Leslie Orr
Leslie_Orr@urmc.rochester.edu
585-275-5774
University of Rochester Medical Center
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Response to immune protein determines pathology of multiple sclerosis
2. Tips from the American Journal of Pathology
3. Tips from the American Journal of Pathology
4. New insight into Alzheimers disease pathology
5. Association for Molecular Pathology joins ACLU to challenge gene patents
6. Tips from the American Journal of Pathology
7. Shaw to receive prestigious honor for plant pathology research
8. Ewen Callaway named 2009 APS Plant Pathology Journalism awardee
9. Small molecule inhibits pathology associated with myotonic dystrophy type 1
10. K-States plant pathology head named fellow of Phytopathology Society
11. Tips from the American Journal of Pathology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2015)... Conn. , Feb. 12, 2015 NXT-ID, ... or the "Company"), a biometric authentication company focused on ... has filed provisional patent 62/113114 for DISTRIBUTED ... DEVICES. The patent further establishes NXT-ID,s position ... its intellectual property portfolio the ability for multiple devices ...
(Date:2/5/2015)... North Carolina , 5. Februar 2015 ... Jahr als spezialisiertes Logistikunternehmen und hat eine ... einzige klinische Logistikfirma (Clinical Logistics Organization – ... der neuen Kampagne lautet First , ... Foto: http://photos.prnewswire.com/prnh/20150205/173753 ...
(Date:2/5/2015)... Jan. 27, 2015   Marvin Test ... deployed, innovative test solutions for military, aerospace, ... of its TS-323 GENASYS Test Platform ... (LMSSC). GENASYS is a high-performance PXI-based system ... applications that require performance functional testing. GENASYS ...
Breaking Biology News(10 mins):NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4
... Insulin resistance, the hallmark of type 2 diabetes and ... an apparent contributor to muscle wasting and severe fat ... And in an animal study, a diabetes drug ... wasting and fat loss, the main consequences of a ...
... RICHLAND, Wash. -- An analytical chemist at the ... recognized with a National Institutes of Health Director,s New ... to make new research and clinical diagnostic tools that ... technologies. The award, which comes with a $1.5 ...
... University of North Carolina at Chapel Hill School of ... received prestigious awards from the National Institutes of Health ... Klaus Hahn, Ph.D., and Mark Zylka, Ph.D., have ... is also in the UNC College of Arts and ...
Cached Biology News:Diabetes drug shows promise in fighting lethal cancer complication 2Diabetes drug shows promise in fighting lethal cancer complication 3PNNL chemist earns NIH New Innovator Award 2PNNL chemist earns NIH New Innovator Award 3UNC scientists garner new NIH awards for high risk, transformative research 2UNC scientists garner new NIH awards for high risk, transformative research 3UNC scientists garner new NIH awards for high risk, transformative research 4
(Date:3/4/2015)... -- In an article published and posted online today, ... review the clinical aspects of diseases caused by 5 ... article, "Clinical Management of Potential Bioterrorism-Related Conditions," was published ... New England Journal of Medicine . ... Tom Inglesby—review the clinical management of conditions resulting from ...
(Date:3/4/2015)... , Mar. 04, 2015 Research and ... the addition of Jain PharmaBiotech,s new report ... their offering. This report follows ... characteristic that can be objectively measured and evaluated ... processes as well as pharmacological responses to a ...
(Date:3/4/2015)... Proove Biosciences , a commercial ... to announce the launch of their CME-accredited course ... of Pain”. , The continuing medical education program ... year. The focus of the program is to ... treatments, integrate appropriate pain management techniques, and incorporate ...
(Date:3/4/2015)... San Jose, California (PRWEB) March 04, 2015 ... Chain Reaction (PCR) represents one of the fastest growing ... among cell biologists in subcellular visualization is driving growth ... The need for deeper understanding of gene expressions will ... reagents market. Expanding applications in fields ranging from pharma, ...
Breaking Biology Technology:Latest Clinical Information On Bioterrorism Threats 2Global Biomarkers Report 2014-2024 - Technologies, Markets and Companies 2Global Biomarkers Report 2014-2024 - Technologies, Markets and Companies 3Proove Biosciences Launches CME Accredited Program with Medscape 2Proove Biosciences Launches CME Accredited Program with Medscape 3Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 2Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 3Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 4
... May 27 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE ... been enrolled in its randomized, double-blind trial evaluating nimotuzumab in ... Institute - New Hope. This trial initiation follows recent clearance ... allowing the Company to enroll patients at US clinical ...
... WALTHAM, Mass. , May 27 Repligen Corporation ... Drug Administration (FDA) and the European Medicines Agency (EMA) have ... Phase 3 study to establish the utility of RG1068, synthetic ... pancreas (Phase 3 re-read).  The FDA and EMA have agreed ...
... engineering in the College of Engineering at Virginia Tech, ... Award to support development of a carbon nanotube-enhanced composite ... of huge wind turbine blades. Powe awards provide ... (ORAU) member institutions. These awards are intended to enrich ...
Cached Biology Technology:YM BioSciences enrolls first US patient in Phase II randomized, double-blind brain metastases trial for nimotuzumab 2YM BioSciences enrolls first US patient in Phase II randomized, double-blind brain metastases trial for nimotuzumab 3YM BioSciences enrolls first US patient in Phase II randomized, double-blind brain metastases trial for nimotuzumab 4YM BioSciences enrolls first US patient in Phase II randomized, double-blind brain metastases trial for nimotuzumab 5YM BioSciences enrolls first US patient in Phase II randomized, double-blind brain metastases trial for nimotuzumab 6Repligen Announces FDA and EMA Approval of Re-analysis of Images from Phase 3 Trial of RG1068 for Pancreatic Imaging 2Repligen Announces FDA and EMA Approval of Re-analysis of Images from Phase 3 Trial of RG1068 for Pancreatic Imaging 3Repligen Announces FDA and EMA Approval of Re-analysis of Images from Phase 3 Trial of RG1068 for Pancreatic Imaging 4Repligen Announces FDA and EMA Approval of Re-analysis of Images from Phase 3 Trial of RG1068 for Pancreatic Imaging 5Powe Award supports development of nanocomposites to monitor wind turbine blade structure 2
ma. plate stack height 70mm...
... MBS Satellite Thermal Cycler (MBS) ... solution for medium to high ... combines the latest in satellite ... and PC control, resulting in ...
45° Fixed Angle Rotor for use in the IEC Centra CL2, Centra CL3/CL3R, HN-SII, and the Centra-MP4/MP4R....
Glycerokinase; from Bacillus stearothermophilus...
Biology Products: